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BACKGROUND: Identification of early molecular pathway changes may be useful as biomarkers for tumour response/resistance
prediction, and here we provide direct in vivo proof of this concept. The type 1 insulin-like growth factor receptor (IGF1R) has been
implicated in various aspects of adenoma development and metastasis. We show here that, in murine intestinal adenomas acutely
exposed to a small molecular inhibitor of EGFR (gefitinib), there is concurrent suppression of EGFR downstream signalling and
induction of IGF signalling. We therefore tested the hypothesis that blockade of EGFR signalling was being tempered by
compensatory activation of the IGF pathway by examining the effect of chronic suppression of IGF1R using AZ12253801, a small
molecular tyrosine kinase inhibitor of IGF1R.
METHODS: Male Apcmin/þ mice with an intestinal tumour burden were exposed to a single dose of an inhibitor against EGFR (gefitinib),
IGF1R (AZ12253801), 0.5% Tween 80 or combined EGFR/IGF1R inhibitor and culled 4 h post dosing. Tumour tissue was analysed to
detect the early molecular pathways induced and anti-tumour phenotypic changes. Cohorts of male Apcmin/þ mice (n¼ 15–17)
were subsequently treated with gefitinib for a period of 8 weeks and subsequently exposed to single (either gefitinib or
AZ12253801) or combined (gefitinib and AZ12253801) therapy. We also included a vehicle-treated cohort, which was never
exposed to gefitinib and became symptomatic of the disease by day 150.
RESULTS: Both single treatments delayed the onset of disease symptoms. Combined dosing with gefitinib and AZ12253801 similarly
delayed the onset of symptoms, and at 200 days suppressed small intestinal tumourigenesis more effectively than either treatment
alone (median small intestinal adenoma volume (47mm3 (comb) vs 248mm3 (AZ12253801), P¼ 0.0003 and 47mm3 (comb) vs
123mm3 (gefitinib), P¼ 0.0042, Mann–Whitney (two-sided) test).
CONCLUSION: Our data provide evidence in support of the use of combinatorial therapy, and establishes the need to further define the
precise benefit in vivo.
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Since the discovery of the benefit of EGFR-targeted monoclonal
antibody therapy in patients with KRAS wild-type metastatic
colorectal cancer (Karapetis et al, 2008), it has become increasingly
important to understand the mechanisms operating in tumours
that eventually develop drug resistance. Much recent research has
focused on the use of cell culture and xenograft approaches (Guix
et al, 2008; Haluska et al, 2008; Hynes and MacDonald, 2009).
Here, we extend that approach to an autochthonous mouse model,
namely the Apcmin/þ mouse, which develops multiple intestinal
adenomas as a result of Wnt pathway activation. The Apcmin/þ
mouse is of particular relevance as we show that harvested colon
adenomas are wild type for K-ras and therefore relevant for the
study of EGFR-targeted therapy and resistance.
The type 1 insulin-like growth factor receptor (IGF1R) has been
implicated in various aspects of tumour development and
metastasis (Chitnis et al, 2008; Pollak, 2008) with overexpression
of IGF1R and its ligands IGF1 and IGF2, a common finding in
malignant disease (Furstenberger and Senn, 2002). It has been
suggested that signalling through type 1 IGF1Rs may confer
resistance to EGF receptor family blockade (Lu et al, 2001;
Jones et al, 2004; Buck et al, 2008; Guix et al, 2008) and is activated
in response to chemotherapy for treatment of colorectal cancer
(Dallas et al, 2009). Interestingly, resistance to IGF1R-targeted
therapies has been demonstrated in a reciprocal fashion with
upregulation of EGFR and its ligands suggesting that EGFR
pathway activation may be an alternative route for growth signals
to be transmitted in presence of inhibition of IGF1R signalling
(Haluska et al, 2008; Huang et al, 2009). Clinical evidence
supporting IGF1R as a treatment target for Ewing’s sarcoma,
adrenocortical carcinoma and non-small cell carcinoma (Carden
et al, 2009) highlights the need to understand the resistance
pathways, which will emerge in response to antagonism of the
IGF1 receptor. Given the possible bidirectional cross-communica-
tion between EGFR and IGF1R pathways it is not surprising that
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research has been directed towards combination-targeted therapy
against both these pathways.
We show here that acute administration of gefitinib inhibits
EGFR signalling while also activating the IGF1R pathway in
adenomas developing in the Apcmin/þ mouse, an in vivo
physiologically relevant model of intestinal tumourigenesis. This
led us to test the efficacy of combined EGFR/IGF1R antagonism
compared with monotherapy with each drug. This is the first
long-term study of these treatment approaches in an autochtho-
nous model of K-ras wild type intestinal tumourigenesis to
examine tumour phenotypic change, adding significantly to the
body of evidence supporting the importance of EGFR and IGF1R
interactions.
MATERIALS AND METHODS
Animals
All experimental male Apcmin/þ mice were in-bred on a C57BL/6
background for at least 12 generations and housed in cages (max
three per cage) with a 12h day/light cycle. Mice received expanded
RM(3) diet (Special Diet Services, Essex, UK) and tap water
ad libitum. Weaning took place at B4 weeks of age. Procedures
involving animals and their welfare were conducted in accordance
with the institutional guidelines that comply with United Kingdom
national policies (Animals (Scientific Procedures) Act 1986). The
Apcmin/þ mice were genotyped at 6–8 weeks of age using tail tip
material. Further details are provided in Supplementary Information.
Pyrosequencing for K-ras mutations
To detect murine K-ras mutations in codons 12/13 and 61
pyrosequencing technology was employed. Codons 12/13 and 61
were initially amplified by PCR using the following primer
sequences: codons 12/13 forward (50-GGCCTGCTGAAAATGACT
GA-30) and reverse (50-CGCAGACTGTAGAGCAGCGTTAC-30),
codon 61 forward (50-TGTTTCTCCCTTCTCAGGACTC-30) and
reverse (50-AGAAAGCCCTCCCCAGTTC-30). The sequencing primers
for codon 12/13 were 50-CTTGTGGTGGTTGGAG-30 and codon 61
50-GGATATTCTCGACACAGC-30. Pyrosequencing was semi-auto-
mated using the Pyromark ID Qiagen System (West Sussex, UK)
and both assays were designed to detect all possible mutations in the
codons examined. See Supplementary Information for further detail.
Allelic discrimination assay for B-raf V600E mutation
Amplification of a specific sequence of target DNA within the B-raf
gene was achieved using forward (50-TTCATGAAGACCTCACAGT
AAAAATAGG-30) and reverse (50-TCGATGGAGTGGGTCCCA-30)
primer sequences. Thereafter TaqMan probes for hybridisation to
the target sequence within the PCR product were used to detect
wild-type or V600E B-raf mutation. The probe sequences were
B-raf wild type (VIC-50-AGCTACAGTGAAATC-30), B-raf V600E
(6FAM-50-CTACAGAGAAATCTC-30). See Supplementary Methods
for further detail.
Materials for injection
Small molecular tyrosine kinase inhibitors of the epidermal growth
factor and type 1 IGF receptors, gefitinib and AZ12253801,
respectively, were made available by AstraZeneca (Cheshire, UK).
Gefitinib was suspended in purite water containing 0.5% Tween 80
for acute experiments (or 1% Tween 80 for chronic exposure
experiments or as indicated) and injected via the intra-peritoneal
(i.p.) route at a dose of 75mg kg1. The AZ12253801 was
suspended in purite water containing 1% Tween 80 and dosed at
12.5mg kg1 i.p. once daily. Bromodeoxyuridine (Brdu, GE
Healthcare, Amersham, UK) S phase cell labelling experiments
were undertaken using a single i.p. injection of 200 ml (3mgml1)
2 h before death.
Animal dissection/tissue preparation
Male Apcmin/þ mice were culled by cervical dislocation in acute
experiments 4 h following drug administration or in chronic
experiments when mice had reached the defined cohort age.
Following a midline excision, small and large intestines were
identified, removed and flushed using cold tap water. The large
bowel was incised along the mesenteric border to open the luminal
surface to permit resection of colon adenomas proximal to any
adenomas related to rectal prolapse. Colon adenomas were
immediately placed in RNAlater (Applied Biosystems, Austin,
TX, USA) or snap frozen in liquid nitrogen and stored at 801C.
Small intestines were sectioned in the transverse plane at three
1 cm intervals, 10 cm distal to the gastro-duodenal junction and
placed in a fixing parcel of 3m surgical tape before overnight
fixation in 10% formalin. The remaining small intestine and large
intestine were placed on Whatman paper and sectioned along the
mesenteric border to open the luminal surface to facilitate fixation
using methacarn solution (methanol: chloroform: acetic acid;
4 : 2 : 1). Small and large intestine adenoma counts, size measure-
ments and location were recorded before rolling gut tissue into a
Swiss roll, securing and placing in 96% ethanol. Immunohisto-
chemistry and western blotting techniques are included in
Supplementary Materials.
Acute drug exposure experiments in Apcmin/þ mice
To assess the early (4 h) pharmaco-dynamic effects of each drug on
cell death, cell proliferation, immune-reactive staining and protein
changes, small cohorts of three mice (unless otherwise stated) were
used to obtain appropriate adenoma tissue. Mice with an intestinal
adenoma burden (i.e., pale feet) were exposed to agents. Phenotypic
scoring of adenomas is described in Supplementary Materials.
Long-term drug exposure in Apcmin/þ mice
A minimum of 15 Apcmin/þ mice (range 15–17) were used in each
chronic drug exposure cohort. Mice started treatment at a median
age of 56 days for all treatments. Each mouse (except vehicle
controls, cohort D) was exposed to daily i.p. gefitinib (75mg kg1)
for 8 weeks to permit the possible development of gefitinib-
resistant intestinal adenoma clones. Cohort (A) continued daily
gefitinib dosed at 75mg kg1; cohort (B) continued daily gefitinib
75mg kg1 in addition to daily i.p. AZ12553801 dosed at
12.5mg kg1; cohort (C) stopped gefitinib following 8 weeks
treatment and started AZ12553801 as a single agent dosed at
12.5mg kg1 o.d.; and finally cohort (D) received continuous daily
i.p. injections of vehicle control 1% Tween 80 from the outset,
dosed according to body weight. Cohorts A–C were aged to 200
days and then culled. The vehicle control cohort (D) became
symptomatic of adenoma burden, (evidenced by pale feet,
hunching, piloerection or weight lossX10% starting body weight)
and was culled at day 150. Adenomas in the small and large
intestine were counted and measured to enable the calculation of
total adenoma volume. Adenoma location was also recorded.
Statistical analysis
The Mann–Whitney (two-sided) statistics was used to detect
significant differences in adenoma numbers and total adenoma
volumes following chronic drug exposure. Box plots of small and
large intestinal numbers and adenoma volumes were generated
using Minitab software v15 (Minitab Ltd, Coventry, UK). Error
bars on charts represent ±1 s.d. from the mean value and
non-overlapping. P-values of p0.05 were accepted as statistically
significant.
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RESULTS
Apcmin/þ colon adenomas do not harbour mutations in
K-ras or B-raf alleles
To determine K-Ras and B-raf status in adenomas developing in
Apcmin/þ mice, we performed K-ras pyrosequencing for known
mutations in codons 12, 13 and 61 and allelic discrimination assays
for B-raf V600E, which failed to identify mutations in genomic
DNA from 30 individual Apcmin/þ colon adenomas harvested from
29 mice (data not shown).
Acute in vivo EGFR inhibition suppresses EGFR signalling,
induces anti-tumour pharmacodynamic changes and
activates the IGF1R receptor in Apcmin/þ colon adenomas
We next tested the effects of acute EGFR blockade using gefitinib
in adenoma bearing Apcmin/þ mice. Four hours following exposure
to 75mg kg1 gefitinib we observed reduced levels of phosphory-
lated EGFR in colon adenomas and suppressed downstream
phosphorylation of ERK and AKT (Figure 1A–D). We also
observed activation of the IGF1 receptor as indicated by increased
levels of IGF1R phosphorylation at tyrosine 1316 (Figure 1E).
Phenotypically, gefitinib exposure led to increased levels of
apoptosis as scored by both H and E staining and the presence
of cleaved caspase-3. In both the small and large bowel there was
evidence of perturbed cell cycling. In small intestinal adenomas,
levels of Brdu labelling were unchanged at 4 h. However, there was
an increase in the number of mitotic figures, suggestive of an M
phase arrest (Figure 2A–D). In colonic adenomas, we observed a
direct reduction in Brdu labelling (Figure 2E), although there was
no change in mitotic counts (data not shown).
In light of the ability of EGFR inhibition to suppress down-
stream signalling in intestinal adenomas, induce favourable
pharmacodynamic change and increase IGF1 receptor signalling,
we next investigated the long-term effects of single agent EGFR
antagonism, single agent IGF1R inhibition and combination EGFR
and IGF1R inhibition.
Chronic EGFR inhibition suppresses Apcmin/þ intestinal
tumorigenesis
The Apcmin/þ mice exposed daily to 75mg kg1 gefitinib were
culled at 200 days. Vehicle-treated animals developed an overt
phenotype before reaching 200 days and were culled at 150 days.
Median colon adenoma numbers at death were significantly
reduced in gefitinib-treated animals compared with vehicle
treatment (2 vs 8 colon adenomas, P¼ 0.002; Figure 3D). As no
difference was observed in colon adenoma volume between
gefitinib and vehicle treatments (Figure 3C), this suggests that
the reduced number of colon adenomas in gefitinib-treated mice
grew to a larger size, presumably as a direct consequence of
enhanced longevity. Despite the suppression of disease symptoms
and consequent increased survival, no differences were observed in
the median number of small intestinal adenomas (37.5 vs 29,
P¼ 0.2664; Figure 3B) or small intestinal adenoma volumes (128 vs
123mm3, P¼ 0.4998; Figure 3A), indicating that following gefitinib
exposure, a longer period of time is required to develop the same
adenoma burden. We therefore interpret this data to argue that
gefitinib exposure suppresses adenoma development in both small
and large intestine.
Chronic IGF1R inhibition fails to inhibit Apcmin/þ
intestinal tumourigensis
The Apcmin/þ mice were initially treated daily with 75mg kg1
gefitinib for 8 weeks, and were subsequently exposed to a daily
dose of 12.5mg kg1 AZ12253801. Mice were then killed and
analysed at 200 days of age. There was an increase in median small
intestine adenoma volume relative to the vehicle cohort culled at
150 days (128.5 vs 248mm3, P¼ 0.0382; Figure 3A). There was no
difference in small intestinal adenoma count (37.5 vs 48,
P¼ 0.0668; Figure 3B), indicating that adenomas grew to a larger
size in the AZ12253801-treated cohort. There were also no
differences in either median colon adenoma volume (158.5 vs
19.5mm3, P¼ 0.2280; Figure 3C) or colon adenoma number. These
data suggest that exposure to AZ12253801 suppressed adenoma
development in the large intestine, as adenoma burden remained
the same, despite increased cohort time. Notably, there was a
higher small intestinal adenoma burden, presumably as a direct
consequence of increased longevity.
Chronic EGFR/IGF1R inhibition maximally suppresses
Apcmin/þ small intestinal tumourigenesis
The Apcmin/þ mice initially treated with daily 75mg kg1 gefitinib
for 8 weeks, were subsequently treated with daily gefitinib in
combination with 12.5mg kg1 AZ1225380. At 200 days, combined
treatment resulted in significantly reduced small and large
intestinal tumourigenesis relative to vehicle as measured by both
adenoma number and volume (median number small intestinal
adenomas 37.5 vs 20, P¼ 0.0222; median number colon adenomas
8 vs 3, P¼ 0.0003; median small intestine adenoma volume 128.5 vs
47mm3, P¼ 0.0034; median colon adenoma volume 158.5 vs
10.5mm3, P¼ 0.0150; Figure 3A–D). The combination of EGFR/
IGF1R blockade therefore reduces both small and large intestinal
tumourigenesis. When comparison is made between the three
chronic treatment regimes at 200 days, combination treatment was
observed to reduce the median small intestinal adenoma number
compared with AZ12253801 (20 (combo) vs 48 (AZ12253801),
P¼ 0.0004) but not against gefitinib (20 (combo) vs 29 (gefitinib),
P¼ 0.22; Figure 3B). Critically, combination treatment markedly
reduced the median small intestinal adenoma volume compared
with either single treatment (47mm3 (comb) vs 248mm3
(AZ12253801), P¼ 0.0003 and 47mm3 (combo) vs 123mm3
(gefitinib), P¼ 0.0042; Figure 3A). In the large intestine, combined
therapy reduced colon adenoma number compared with
AZ12253801 treatment, but not against gefitinib (3 (combo) vs 5
(AZ12253801), P¼ 0.0187 and 3 (combo) vs 2 (gefitinib), P¼ 0.718;
Figure 3D). No differences were observed in median colon
adenoma adenoma volume between the treatments (10.5mm3
(combo) vs 19.5mm3 (AZ12253801), P¼ 0.0648 and 10.5mm3
(combo) vs 8mm3 (gefitinib), P¼ 0.482; Figure 3C).
Acute phenotypic changes induced in small intestinal
treated with EGFR/IGF1R inhibition
We next sought to dissect the mechanisms of response to these
agents in terms of the acute effects upon Apcmin/þ intestinal
adenomas with respect to cell death and proliferation rates.
Following 4 h exposure of Apcmin/þ mice to combined EGFR/
IGF1R antagonism, there is a reduction in small intestinal
adenoma mitotic scoring (0.4%±0.3 (combo) vs 2.1%±0.4
(gefitinib), P¼ 0.04) and Brdu cell labelling (16.9%±4 (combo)
vs 28.6%±1.4 (gefitinib), P¼ 0.04) compared with gefitinib,
without the detection of an increased level of small intestinal
adenoma apoptosis (1.4%±0.5 (combo) vs 1.9±0.4 (gefitinib)) or
caspase-3 scoring (5.2%±3.8 (combo) vs 10.1%±0.7 (gefitinib).
The molecular effects of acute IGF1R inhibition
The immediate effect of gefitinib exposure is to reduce phosphory-
lation of EGFR, ERK and AKT with reciprocal phosphorylation of
the IGF1R (Figure 4). We next investigated the molecular changes
occurring 4 h following IGF1R inhibition. Inhibition of IGF1R
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signalling by AZ12253801 alone results in an expected reduction in
phosphorylation of AKT (Figure 4A and D) and an apparent
paradoxical ‘rebound’ increased phosphorylation of the IGF1R
(Figure 4A and C). In the context of a reduced level of EGFR
phosphorylation (Figure 4A and B), AZ12253801 also induced
phospho-ERK1/2 signalling (Figure 4A and E). Thus we can
hypothesise that inhibition of IGF1R initially suppresses down-
stream signalling as evidence by the reduction in phospho-AKT,
but this change leads to a loss of feedback upstream resulting in
increased IGF1R phosphorylation. Such rebound activation of the
IGF1R pathway following IGF1R inhibition may explain the
increased level of ERK phosphorylation or alternatively reflect
altered EGFR trafficking.
The molecular effects of acute combination therapy
In view of the signalling changes described for EGFR and IGF1R
inhibition alone we anticipated that combined EGFR/IGF1R
inhibition would produce either competing or additive molecular
effects 4 h after exposure. The former is demonstrated for both
EGFR and ERK phosphorylation (Figure 4B and E) where the level
of activity is between that for each agent alone. For phospho-AKT
suppression, we observed an additive effect compared with either
treatment in isolation (Figure 4D). For phospho-IGF1R, combina-
tion therapy resulted in either similar (IGF1R inhibition) or
reduced (EGFR inhibition) levels compared with individual
treatments (Figure 4C).
Total EGFR
P-EGFR
Total ERK
P-ERK
Total AKT
P-AKT
Total IGF1R
Tubulin
pY1316 IGF1R
Vehicle
0.2
0.25
0.3
P-EGFR densitometry P-ERK densitometry
0.8
1
1.2
0
0.05
0.1
0.15
t4 Veh 1%
0
0.2
0.4
0.6
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1
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2
2.5
0.4
0.6
0.8
P-AKT densitometry P-IGF1R densitometry
0
0.5
t4 Veh 1%
0
0.2
t4 Veh 1%
Gefitinib
t4 Gef t4 Gef
t4 Gef t4 Gef
Figure 1 (A) Western blot to demonstrate the immediate in vivo effect of gefitinib 75mg kg1 on downstream EGFR signalling in Apcmin/þ colon
adenomas. A 30-mg pooled colon adenoma protein sample was loaded into each well in duplicate. Each loaded sample comprised equivalent amounts of
protein (30 mg) from individual colon adenomas harvested from male Apcmin/þ mice exposed to either vehicle (1% Tween 80) or gefitinib. Colon adenomas
were obtained 4 h post dosing when animals were culled. A total of 26 colon adenomas from three gefitinib-treated mice and 19 colon adenomas from
three vehicle-treated mice were pooled. Loading controls were either b actin or tubulin. (B–E) Densitometry of total phospho-protein levels normalised
relative to loading control with value ranges indicated by error bars.
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The molecular effects of chronic gefitinib or AZ12253801
exposure
Finally, we examined signal transduction pathway changes
associated with chronic administration to determine potential
tumour resistance mechanisms and to ask if the acute signalling
pathway changes bear any direct relevance to those signalling
pathways altered following chronic exposure.
Chronic treatment with gefitinib (relative to vehicle) results in
increased protein levels of total EGFR, total IGF1R and phospho-
IGF1R (Figure 5A, B, E and F). Given that levels of both EGFR and
ERK phosphorylation (Figure 5A, C and D) are not elevated, this
argues that IGF1R activity may be driving resistance to therapy.
However, despite evidence of activation of the IGF1 receptor,
phosphorylation of the downstream effectors usually associated
with this pathway (AKT and S6 ribosomal protein densitometry
data are not shown) is not seen. This suggests that, in the setting of
chronic blockade of EGFR, activation of the IGF1R pathway is
mediating adenoma growth through alternative, unidentified
mechanisms. Furthermore, the observation that acute gefitinib
exposure induced activation of the IGF1R at 4 h highlights that
resistance mechanisms are initiated early in a treatment schedule
and that they can be predicted by this method.
The only change observed following chronic AZ12253801 was a
reduction in phospho-EGFR levels relative to vehicle (Figure 5).
Given the suppressed level of phospho-EGFR, the maintenance of
phospho-ERK (Figure 5C and D) is presumed to be via an EGFR
independent mechanism. Chronic IGF1R inhibition therefore
results in similar pathway dynamics to acute IGF1R inhibition,
where we also observed suppression of phospho-EGFR. If the level
of phospho-ERK is crucial in driving IGF1R resistant adenomas,
then the acute data showing an increase in phospho-ERK
potentially reflects a mechanism of resistance. This raises the
possibility that IGF1R inhibitor resistance may be overcome by
combined IGF1R and MEK inhibition.
DISCUSSION
In this paper we have described the acute and chronic effects of
inhibiting EGFR and IGF1 alone and in combination in the Apcmin/þ
mouse. Given that K-RAS and B-RAF wild type status is predictive
of EGFR-targeted response in patents (Di Nicolantonio et al, 2008;
Karapetis et al, 2008), we first determined K-ras and
B-raf status in adenomas developing in the Apcmin/þ mouse. The
observation that these adenomas remain wild type for K-ras and
B-raf underscores the relevance of this model for studying EGFR
blockade. In terms of responsiveness to agents that target EGFR
and IGF1R, there is increasing evidence for cross-communication
between these two pathways from both cell line and xenograft
studies (Buck et al, 2008; Guix et al, 2008; Haluska et al, 2008;
Desbois-Mouthon et al, 2009; Huang et al, 2009; Kaulfuss et al,
2009). Here we have now extended this analysis to an auto-
chthonous in vivo animal model.
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Figure 2 The acute pharmacodynamic effects of gefitinib 75mg kg1 (i.p.) compared with vehicle control (0.5% Tween 80) in Apcmin/þ small intestinal (SI)
adenomas (A–D) and colon adenomas (E) 4 h post dosing. (A) Gefitinib-induced apoptosis in SI adenomas (0.45%±0.15 (Veh) vs 1.96%±0.36 (Gef),
P¼ 0.04) and (B) cleaved caspase-3 staining (4.4%±0.7 (Veh) vs 10.1%±0.7 (Gef), P¼ 0.04). (C) Increased SI mitotic scoring (1.4±0.2 (Veh) vs 2.1%±0.4
(Gef), P¼ 0.04) with (D) unchanged Brdu labelling (32.4%±5.5 (Veh) vs 28.6%±1.4 (Gef), P¼ 0.3) following gefitinib exposure. (E) Colon adenoma Brdu
labelling is reduced following gefitinib exposure (21.1%±3 (Veh) vs 12.3%±5.2 (Gef), P¼ 0.04). A minimum of three tumours were scored from each
animal with three mice for each experimental treatment (*P¼ 0.04).
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Acute exposure of Apcmin/þ mice to gefitinib suppressed EGFR,
ERK and AKT phosphorylation in keeping with its known action as
an inhibitor of EGFR tyrosine kinase activity (Wakeling et al,
2002). This, combined with published evidence of the importance
of EGFR signalling in Apcmin/þ mouse intestinal adenomas (Moran
et al, 2004) including genetic manipulation studies with hypo-
morphic EGFR alleles (EGFRwa2 allele) and pharmacologic
manipulation (Roberts et al, 2002), supports a role for EGFR in
intestinal adenoma development. Short-term exposure to gefitinib
led to increased apoptosis and mitotic blockade in small intestinal
adenomas and reduced cell cycling in colon adenomas. We also
observed increased IGF1R phosphorylation. These observations
predict that long-term exposure to gefitinib will improve survival
by delaying the development of intestinal adenomas and implicit
in this the notion that gefitinib resistance may develop, possibly
through deregulation of pathways such as IGF1R. This early
observation indicated to us that this model would be useful to test
the effect of IGF1R antagonism alone and in combination with
gefitinib.
Chronic administration of gefitinib reduced intestinal tumouri-
genesis as a consequence of cell cycle inhibition. This observation
of perturbed cell cycling supports an earlier report of gefitinib
reducing proliferation, the number of aberrant crypt foci and
colonic microadenomas in an azoxymethane model of colonic
carcinogenesis (Fichera et al, 2007). We have confirmed the
significance of early gefitinib induced IGF1R signalling in colon
adenomas in relation to resistance as IGF1R and IGF1R
phosphorylation are increased at the protein level in chronic
gefitinib exposed resistant adenomas. Interestingly phospho-AKT
and phospho-S6P were not activated, suggesting an alternate
pathway is responsible for signal transduction promoting adenoma
growth. It appears that adenoma cells in an attempt to overcome
EGFR blockade also increase EGFR protein but fail to increase
activation of EGFR signalling as shown by an absence of change
in EGFR phosphorylation and reduced ERK phosphorylation.
Previous work has shown that inhibition of EGFR-ERK pathway
activity by EGFR blockade enhances IRS1 interaction with PI3K-
AKT signalling (Buck et al, 2008). This together with our finding of
increased IGF1R activity following EGFR blockade led us to expect
increased AKT phosphorylation, however, we failed to demon-
strate this in vivo following chronic gefitinib treatment.
The acute increased IGF1R activity in colon adenomas following
exposure to EGFR blockade raises the possibility of testing tumour
specimens or circulating tumour cells (de Bono et al, 2007) for
their initial response to drug. Such responsiveness could then be
considered in determining therapeutic combinations. To address
this approach, we determined if the acute activity in IGF1R
predicted improved outcome (in terms of anti-adenoma effect)
when IGF1R inhibition was combined with EGFR blockade. We
have demonstrated suppression of intestinal tumourigenesis with
combination treatment relative to vehicle as evidence by an almost
three-fold reduction of median small intestinal adenoma volume
and 16-fold reduction of median colon adenoma volume. The
reduction in small intestinal adenoma volume remains when
compared with gefitinib treatment alone reinforcing the potential
therapeutic advantage of adding IGF1R blockade to gefitinib.
In terms of understanding the mechanism of the adenoma
suppression with combined EGFR/IGF1R treatment, we undertook
protein analysis for 4 h following EGFR and IGF1R blockade alone
and in combination. We anticipated demonstrating maximal
suppression of AKT phosphorylation for the combination against
both drug comparisons (Buck et al, 2008; Guix et al, 2008),
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Figure 3 Box plots illustrating the treatment effects of EGFR inhibition (gefitinib), IGF1R inhibition (AZ12253801), vehicle (1% Tween 80) and combined
EGFR/IGF1R inhibition on Apcmin/þ mice. Cohorts of male Apcmin/þ mice (n¼ 15–17) were treated with gefitinib for a period of 8 weeks and subsequently
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volumes at death for both the small intestine and colon with associated P-values (two-sided Mann–Whitney test). A total of 14 mice received daily vehicle
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however, we only found suppression of tumoural AKT signalling
for combination against vehicle and gefitinib treatments
(Figure 4D), but not IGF1R inhibition. Expectation of maximal
suppression of AKT signalling for the combination does assume a
simple additive relationship in terms of the effects seen by either
drug in isolation, and it is possible that in combination the
relationship between the pathways is more complicated such that
at the level of AKT, pathway inhibition and loss of negative
feedback does not equate with an additive outcome in vivo as
expected. Therefore in terms of understanding the signalling
responsible for combinatorial adenoma suppression we conclude
that relative to vehicle, a reduction in EGFR and AKT phosphory-
lation appears to be important. At the 4 h timepoint chosen, we
have been unable to clearly dissect the anti-tumour mechanism of
dual therapy in terms of cell death/turnover. Previous reports of
enhanced apoptosis with dual blockade of EGF/IGF1 receptors
have been published with (Guix et al, 2008) or without increased
anti-proliferative effects (Buck et al, 2008; Haluska et al, 2008).
The IGF1R receptor has been implicated in the development of
tumours in various settings (Pollak, 2008) and we therefore
anticipated that inhibition of the IGF1R would be of potential
therapeutic significance in this model. We observed that exposure to
chronic IGF1R inhibition may delay small intestinal adenoma
growth, whereas combined IGF1R/EGFR blockade suppresses growth
relative to single agent treatments. This suggests continued EGFR
inhibition is required to promote IGF1R adenoma expression and
the target of AZ12253801, to elicit an anti-adenoma response. In
demonstrating EGFR blockade enhanced IGF1R activity we have
provided support for the in vivo proof of concept that IGF1R-
targeted therapy may induce an anti-adenoma effect in adenomas
expressing high receptor levels driven by continued EGFR blockade,
and is a potential predictive biomarker (Zha et al, 2009).
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Figure 4 (A) Western blotting to demonstrate the immediate molecular signalling changes induced in Apcmin/þ colon adenomas 4 h post single dosing
with vehicle (1% Tween 80), gefitinib 75mg kg1 o.d., AZ12253801 12.5mg kg1 o.d. and combined gefitinib and AZ12253801. A volume of 30 mg pooled
colon adenoma protein samples were loaded into wells in duplicate with a single positive control. Each loaded sample comprised equivalent amounts of
protein (30 mg) from individual colon adenomas harvested from three male Apcmin/þ mice exposed to either vehicle, gefitinib, AZ12253801 or combined
geftitinb and AZ12253801 for 4 h. A total of 19 colon adenomas were pooled from vehicle-treated mice, 26 colon adenomas from gefitinib-treated mice,
9 colon adenomas from AZ12253801-treated mice and 17 colon adenomas from combined-treated mice. Loading controls were either b actin or tubulin.
(B–E) Densitometry readings for each phosphorylated protein were normalised relative to loading controls. Error bars indicate value ranges. Abbreviations:
AZ12253801¼ IGF1R inhibitor; combo¼ combined EGFR/IGF1R inhibition; Gef¼ gefitinib; Veh¼ vehicle.
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Signalling pathway changes in response to acute IGF1R
inhibition (Figure 4) included an expected reduction in AKT
phosphorylation but also a paradoxical increase in IGF1R
phosphorylation along with an increased level of ERK phosphory-
lation despite a reduction in EGFR activity. We suggest that
AZ12253801 initially suppresses IGF1R phosphorylation leading to
the observed reduction in AKT activity, with this itself triggering
feedback leading to increased IGF1R phosphorylation. This
‘rebound’ activity in IGF1R signalling may account for the marked
increase in ERK phosphorylation. Alternatively, the increased ERK
activity may be consequent upon subtle changes in EGFR
trafficking or secondary to suppression of cytoplasmic phospha-
tases DUSP 6, 7 or 9 (Owens and Keyse, 2007).
Taken together, we speculate that the predominant initial
response to AZ12253801 is suppression of AKT signalling, followed
by a switch to predominant ERK signally resulting in loss of
response and the observed increased adenoma growth. If this
hypothesis is correct it may be possible to suppress or prevent
tumour resistance to IGF1R blockade by inhibiting ERK activity;
indeed we do see partial inhibition of ERK phosphorylation by
adding gefitinib to IGF1R inhibition (Figure 4E). Such incomplete
ERK inhibition may explain why combination with EGFR blockade
therapy ultimately fails, and also suggests that more potent
suppression of ERK activity for example with a MEK inhibitor in
the context of IGF1R inhibition may be a preferred combination
(Buck et al, 2008).
Chronic exposure to IGF1R inhibition also reduces EGFR
phosphorylation. Recent studies support a role for EGFR family
members in resistance to IGF1R inhibitors (Haluska et al, 2008;
Desbois-Mouthon et al, 2009; Huang et al, 2009) and suggest that
at least in the Apcmin/þ mouse model the response to chronic
IGF1R therapy does not involve increased activity in EGFR. The
mechanism of reduced EGFR phosphorylation is unclear.
In summary we have shown that, in Apcmin/þ intestinal
adenomas, acute EGFR blockade by gefitinib reduces EGFR
signalling, but activates IGF1R, a potential resistance pathway.
Chronic monotherapy against either EGFR or IGF1R influences
adenoma growth, but combination EGFR/IGF1R blockade pro-
duced the most effective adenoma suppression. Our data therefore
support the concept of EGFR resistance mediated through induced
IGF1R signalling supporting the need for further enquiry regarding
the potential utility of combinatorial therapy.
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Figure 5 (A) Western blot to demonstrate the molecular signalling activity in colon adenomas obtained from male Apcmin/þ mice exposed to long-term
vehicle, gefitinib 75mg kg1 o.d. or AZ12253801 12.5mg kg1 o.d. treatment (A). Colon adenomas were obtained at the time of death (150 days for
vehicle and 200 days for mice receiving treatment). A volume of 30 mg pooled colon adenoma protein samples were loaded into wells in triplicate. Each
loaded sample comprised equivalent amounts of protein (30 mg) from individual colon adenomas harvested from three male Apcmin/þ mice except for
vehicle treatment where two mice were used. In total seven colon adenomas were pooled from vehicle-treated mice, eight from gefitinib-treated mice and
13 from AZ12253801-treated mice. Loading control was tubulin. (B–F) Densitometry values for respective total and phosphorylated proteins.
Phosphorylated proteins were normalised relative to loading control reflecting total levels of protein phosphorylation. Error bars represent ±1 s.d.,
*P¼ 0.04 (Mann–Whitney test).
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